Buzdar, A U <br/><br/>
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Nov 1999 
 - 3412-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.1999.17.11.3412  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Cyclophosphamide--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Middle Aged<br/>Neutropenia--chemically induced<br/>Paclitaxel--administration & dosage<br/>Prospective Studies